TMCnet News
Biothera Pharmaceuticals to Present Clinical Data from Phase 2 Triple Negative Breast Cancer Study at ASCO 2019 Annual MeetingEAGAN, Minn., May 16, 2019 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc., which is developing a dectin receptor agonist drug known as Imprime PGG, announced today that it will present primary clinical data from its phase 2 study in chemo-refractory metastatic triple negative breast cancer at the American Society of Clinical Oncology (ASCO) 2019 annual meeting, May 31-June 4 in Chicago. The study is evaluating Imprime PGG in combination with KEYTRUDA (pembrolizumab), an anti-PD-1 therapy from Merck & Co., Inc. (known as MSD outside the United States and Canada), in triple negative breast cancer patients whose disease has progressed following treatment with one or more lines of chemotherapy for metastatic disease. The study is being conducted under a clinical collaboration agreement between Biothera and Merck. Poster presentation details are as follows: Session: Developmental Immunotherapy and Tumor Immunobiology Date and Time: Saturday, June 1, 8:00 AM-11:00 AM CDT Location: Hall A About Biothera Pharmaceuticals, Inc. Contact: |